All PARP Inhibitors Are Not the Same1-3

  • Each PARP inhibitor needs to be assessed based on its own data; data cannot be extrapolated from one PARP inhibitor to another
  • When choosing a PARP inhibitor, it is important to understand pharmacologic properties and data in the specific population under consideration

ZEJULA is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.1

 

ZEJULA has high bioavailability, a long half-life, and extensive tissue distribution1

The Fundamental Differences Among PARP Inhibitors

Preclinical Studies Suggest That Higher Concentrations of a PARP Inhibitor May Be Needed to Induce Cell Death in BRCAwt Tumors4

In an in vitro colony formation assay to measure clonogenic survival after 10-12 days of continuous exposure, BRCA1- or BRCA2-deficient and wild-type embryonic stem cells were treated with KU0058684, a small-molecule PARP inhibitor.4

  • Tumor cell lines without a BRCA mutation have been shown to be less sensitive to PARP inhibition
  • These cells lines responded to higher concentration of PARP inhibitors, resulting in cancer cell death

In Preclinical Models, Niraparib Concentrates in the Tumor, Achieving Significant Tumor Exposure5

Niraparib pharmacokinetics in the tumor and plasma were analyzed using a BRCA1mut xenograft model. All mice were treated at the MTD (niraparib 75 mg/kg daily, olaparib 100 mg/kg) for 5 days and samples were collected on the last day of treatment at 7 different time points.

The clinical significance of in vitro studies is unknown. Mechanism of action statements are not meant to imply efficacy.

ZEJULA Achieves Potent Tumor Growth Inhibition in Xenograft Models of BRCAwt Ovarian Cancer5

The clinical significance of in vitro studies is unknown. Mechanism of action statements are not meant to imply efficacy.

NOVA Is the Only Phase 3 Trial of a PARP Inhibitor to Isolate and Evaluate Efficacy in the gBRCAmut and the Difficult-to-treat Non-gBRCAmut Populations6-9

 

Learn More About the Clinically Rigorous Evaluation of ZEJULA

Select Adverse Reactions Were Dose Dependent and Managed With Dose Modifications in the NOVA Study1

Find the Right Dose for Your Patients Based on the “Weights and Plates” Exploratory Analysis10

TOGETHER with TESAROTM Provides Support for Your Patients

AUC0-24h, area under the curve during 24 hours; bid, twice daily; BRCA, breast cancer susceptibility gene; BRCAmut, BRCA mutated; BRCAwt, BRCA wild type; CEs, carboxylesterases; CR, complete response; F, bioavailability; HRD, homologous recombination deficiency; HRDneg, HRD negative; HRDpos, HRD positive; MTD, maximum tolerated dose; NA, not available; PARP, poly(ADP-ribose) polymerase; PDX, patient-derived xenograft; PFS, progression-free survival; PR, partial response; T1/2, terminal elimination half-life; Vd/F, apparent volume of distribution